Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expedited LITT and Chemoradiation for Newly Diagnosed High Grade Gliomas
NCT02970448Phase 1Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Aug 2017
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temozolomide in high-grade glioma (HGG), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Study safety as determined by the number of patients who experience pre-specified adverse events. Started Aug 2017; status: completed.
02
Drugs
temozolomide
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02970448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970448.